Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 541 to 555 of 1455 results for do not do recommendations

  1. Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer (TA812)

    Evidence-based recommendations on pralsetinib (Gavreto) for treating RET fusion-positive advanced non-small-cell lung cancer in adults.

  2. Early value assessment interim statement (PMG39)

    Early value assessment is a new evidence-based approach designed to improve the care of people and effective use of NHS resources through quicker access to promising health technologies that address national unmet need. It champions stronger partnership working between regulatory, healthcare and research organisations to benefit people and better support innovators while ensuring value for money for the NHS

  3. Flu vaccination: increasing uptake (NG103)

    This guideline covers how to increase uptake of the free flu vaccination among people who are eligible. It describes ways to increase awareness and how to use all opportunities in primary and secondary care to identify people who should be encouraged to have the vaccination.

  4. Research recommendations process and methods guide (PMG45)

    Research recommendations process and methods guide

  5. Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)

    Evidence-based recommendations on enzalutamide (Xtandi) for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.

  6. Ustekinumab for treating moderately to severely active ulcerative colitis (TA633)

    Evidence-based recommendations on ustekinumab (Stelara) for treating moderately to severely active ulcerative colitis in adults.

  7. People and communities - putting you at the heart of our work

    products are focused around the people most directly affected by our recommendations. Involving you in the development of our guidance We

  8. People and communities - putting you at the heart of our work

    products are focused around the people most directly affected by our recommendations. Involving you in the development of our guidance We

  9. Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA722)

    Evidence-based recommendations on pemigatinib (Pemaryze) for relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.

  10. Midostaurin for treating advanced systemic mastocytosis (TA728)

    Evidence-based recommendations on midostaurin (Rydapt) for treating advanced systemic mastocytosis in adults.

  11. Quality standards: process guide (PMG43)

    This guide describes the process NICE uses to develop NICE quality standards

  12. New generation cardiac CT scanners (Aquilion ONE, Brilliance iCT, Discovery CT750 HD and Somatom Definition Flash) for cardiac imaging in people with suspected or known coronary artery disease in whom imaging is difficult with earlier generation CT scanners (DG3)

    Evidence-based recommendations on new generation cardiac CT scanners (Aquilion ONE, Brilliance iCT, Discovery CT750 HD and Somatom Definition Flash) for cardiac imaging in people with suspected or known coronary artery disease in whom imaging is difficult with earlier generation CT scanners

  13. Artificial intelligence-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessment (HTE12)

    Early value assessment (EVA) guidance on artificial intelligence (AI)-derived software to analyse chest X-rays for suspected lung cancer in primary care referra...

  14. Acute coronary syndromes in adults (QS68)

    This quality standard covers diagnosing and managing acute coronary syndromes in adults (aged 18 and over). Acute coronary syndromes are medical emergencies that include myocardial infarction (heart attack) and unstable angina (unexpected, severe chest pain). It describes high-quality care in priority areas for improvement.

  15. Drug misuse prevention (QS165)

    This quality standard covers the prevention or delay of harmful use of drugs by children, young people and adults most likely to start using drugs, or already experimenting or using drugs occasionally. This includes illegal psychoactive substances, solvents, volatile substances, image- and performance-enhancing drugs, prescription-only medicines and over-the-counter medicines. It describes high-quality care in priority areas for improvement.